Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (281-290 of 379) with videos related to

Pageof 38
Sort By:
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
Hemasphere|June 5, 2024
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphomaBerit Müller-Meinhard, Nicole Seifert, Johanna Grund, et al.
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
British Journal of Haematology|March 15, 2023
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphomaJohanna Grund, Katharina Iben, Sarah Reinke, et al.
British Journal of Haematology|July 26, 2022
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphomaSylvia Hartmann, Ahmad Sajad Soltani, Katrin Bankov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialThomas Elter, Peter Borchmann, Holger Schulz, et al.
British Journal of Haematology|September 1, 2018
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapyJan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, et al.
Immunity|December 7, 2007
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cellsElke Pogge von Strandmann, Venkateswara Rao Simhadri, Bastian von Tresckow, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study GroupJan Kriz, Gabriele Reinartz, Markus Dietlein, et al.
Leukemia|August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupCarla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Pageof 38

Showing results (281-290 of 379) with videos related to

Sort By:
Pageof 38
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
Hemasphere|June 5, 2024
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphomaBerit Müller-Meinhard, Nicole Seifert, Johanna Grund, et al.
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
British Journal of Haematology|March 15, 2023
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphomaJohanna Grund, Katharina Iben, Sarah Reinke, et al.
British Journal of Haematology|July 26, 2022
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphomaSylvia Hartmann, Ahmad Sajad Soltani, Katrin Bankov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialThomas Elter, Peter Borchmann, Holger Schulz, et al.
British Journal of Haematology|September 1, 2018
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapyJan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, et al.
Immunity|December 7, 2007
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cellsElke Pogge von Strandmann, Venkateswara Rao Simhadri, Bastian von Tresckow, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study GroupJan Kriz, Gabriele Reinartz, Markus Dietlein, et al.
Leukemia|August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupCarla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Pageof 38